You are here

Novel Methods for Rapid Detection of Infection Agents and the Severity of Cellular Damage

Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: N10PC20233
Agency Tracking Number: 08ST1-0060
Amount: $749,291.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: ST081-003
Solicitation Number: 2008.A
Solicitation Year: 2008
Award Year: 2010
Award Start Date (Proposal Award Date): 2010-06-15
Award End Date (Contract End Date): 2012-06-14
Small Business Information
1165 Chess Drive Suite H
Foster City, CA 94404-
United States
DUNS: 803607154
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Lulu Zhang
 Principal Investigator
 (517) 378-3758
Business Contact
 Aiguo Zhang
Title: President, DiaCarta LLC
Phone: (517) 378-3758
Research Institution
 University of Rochester
 Donna Beyea
518 Hylan Building University of Rochester
Rochester, NY 14627-
United States

 (585) 275-8036
 Nonprofit College or University

Early detection of virulent infectious pathogens is critical to blocking the devastating epidemic spread of the pathogen and the potential harm this could have on our armed forces and general populations. In Phase I, we have utilized the state-of-the-art QuantiGene 2.0 technology to establish an assay for the sensitive quantification of SARS (epidemic spread in 2001) and assessing plasma DNA levels as a measure of the severity of cellular damage induced by a variety of insults, including infectious disease and radiation injury. In this Phase II, we will expand our assay to detect additional pathogens that are currently at epidemic levels worldwide. In addition, we will migrate from a 96-well plate to a chip-based assay platform containing magnetic beads as a reaction surface and portable sample processing/readout device. We will focus on two aims: 1) develop assays for the currently emerging influenza (H1N1) epidemic and tuberculosis; 2) develop a chip-based assay platform and portable device for use as an assay for infectious diseases in resource-limited conditions. The Phase II study will further advance our capability to develop an early detection assay for virulent pathogens and determine the cellular damage caused by all insults using a portable in vitro diagnostic device.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government